Indication
Camrelizumab
5 clinical trials
6 products
Clinical trial
A Randomized, Open Label, Parallel Controlled, Multicenter Phase II Clinical Study of Carelizumab Combined With TCb (Docetaxel+Carboplatin) Versus TCb Neoadjuvant Therapy for Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Product
Carrelizumab + TCb regimenProduct
TCbClinical trial
A Prospective, Multicenter, Double-blind, Randomized Controlled Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced NSCLCStatus: Not yet recruiting, Estimated PCD: 2025-11-22
Product
CamrelizumabClinical trial
Sequential bTAE-HAIC Combined With Lenvatinib and Camrelizumab for Intermediate-advanced Huge Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2025-06-30
Product
LenvatinibClinical trial
A Phase 2 Clinical Trial of Neoadjuvant Camrelizumab Plus Apatinib and Temozolomide in High Risk Clinical Stage Ⅱ-Ⅲ Acral MelanomaStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Transarterial Chemoembolization Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma : a Randomised , Open Label, Multicenter Controlled TrialStatus: Recruiting, Estimated PCD: 2026-06-30
Product
Camrelizumab + Apatinib